top of page

US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.

Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.

HOW WE USE YOUR INFORMATION

to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;

to send marketing communications to you, if applicable and
to comply with our legal and regulatory obligations and bring and defend legal claims.

We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein). 

We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.

If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.

Modern Architecture

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

SHANKAR HARIHARAN, PHD

Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.

Search

Oct 29, 2018

Softhale NV Announces New Board Member

DIEPENBEEK, Belgium, Oct. 30, 2018 /PRNewswire/ — Softhale NV, a pharmaceutical company leveraging its respiratory soft mist inhalation platform to develop and commercialize COPD and asthma treatment products, announced today the appointment of a new independent member to its Board of Directors. Mr. Nevan Charles Elam, J.D., has joined the Board of Directors as of October 2018.

“We are delighted to welcome Nevan on our Board. His rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies will broaden the competencies of our Board and support further development of the company” stated Frank Pieters, Chairman of the Board.

“I am excited to join Softhale’s Board, as I enjoy working with innovative companies that have the potential transform markets and improve patient care.” Mr. Elam continued, “I believe that Softhale has the right combination of a robust device platform along with an experienced and proven management team.”

Mr. Elam, currently CEO and Chairman of Rezolute Inc. and he also serves on the board of directors of Savara Pharmaceuticals (NASDAQ: SVRA) in Austin, Texas. Previously, he served for many years on the Board of Directors of Aerogen, Inc. in Galway, Ireland.

Earlier in his career, Mr. Elam was SVP and Head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar he led the spin out of Pearl Therapeutics to focus on treatments for asthma and COPD (in 2013 Pearl Therapeutics was acquired by AstraZeneca for $1 billion). Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.

Recent Posts

New Procedure Can Restore Function in Severed Facial Nerves in Minutes

https://read.houstonmethodist.org/peg-nerve-fusion-technique

Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device

Theranica's Evidence-Based Wearable Device will be Offered to Members Covered Under Harvard Pilgrim Health Care and Tufts Health Plan...

Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements

PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and...

Comments

Post: Blog2_Post

bottom of page